NIH Panel Releases New COVID-19 Treatment Guidelines Updates
March 25, 2022
The COVID-19 Treatment Guidelines Panel (the Panel) has just released a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.
The Guideline updates include:
- Testing for SARS-CoV-2 Infection. Based on the currently available information, the Panel concludes that there is insufficient evidence to recommend either for or against the use of SARS-CoV-2 serologic testing to assess for immunity or to guide clinical decisions on the use of COVID-19 vaccines or anti-SARS-CoV-2 monoclonal antibodies (mAbs) in certain people.
- Prevention of SARS-CoV-2 Infection. The Panel’s guidelines were revised to include new dosing recommendations for tixagevimab and cilgavimab when used as pre-exposure prophylaxis. This section also discusses some important limitations to the new recommendations. The update is based on the most recent version of the Food and Drug Administration's Emergency Use Authorization, which was revised in response to data that show that the BA.1 and BA.1.1 subvariants of the Omicron variant have a decreased susceptibility to these mAbs.
- Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment and Prevention of COVID-19 When There Are Logistical or Supply Constraints. This new section of the Guidelines incorporates information from the Panel’s previously published statement on patient prioritization for outpatient therapies.
- Granulocyte-Macrophage Colony-Stimulating Factor Inhibitors The text and clinical data table on use of these agents have been updated to include recently published data.
For complete details on these updates, see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.